top of page

Novartis Sets 5% Growth Target Through 2031 as Patent Losses Hit

1h
6 min read

Novartis on November 19 set a goal of about 5% annual sales growth through 2031, the low end of its previous range. The Swiss drugmaker said it expects to grow through its biggest wave of patent losses yet. Its plan is built on new drugs, outside deals and the use of AI in drug development.


  • Novartis guides to a 5% compound annual sales growth rate at constant currency from 2026 to 2031.

  • Peak sales targets rose to $8 billion for Kesimpta and $5 billion each for Scemblix and Leqvio.

  • Cosentyx faces Medicare price cuts in 2028 and loss of exclusivity in 2029.

  • Novartis expects about half its long-term revenue to come from outside assets.

  • 95% of its small molecule projects already use AI, the company says.


An automated liquid handling robot dispenses into rows of drug vials and 96 well plates in a teal lit drug discovery lab at dusk, beside the title Growing Through the Cliff

Novartis set a lower growth bar for the next five years


Novartis now expects net sales to grow about 5% a year at constant currency from 2026 to 2031. The company unveiled the target at its annual Meet Novartis Management event in London. Last year, it guided to 5% to 6% sales growth for 2025 to 2030.


The new figure sits at the low end of that previous range. Novartis also said its core operating income margin is on track to get back to 40% or more by 2029, a target unchanged from earlier guidance. Chief financial officer Mukul Mehta said the margin would dip at least two points in the coming years as patents expire and prices decline.


Investors were not thrilled with the new guidance, and Novartis shares dropped about 3% on the day of the event. The company has had a rough 2026, with late-stage trial failures for some of the drugs it acquired.


Why is Novartis growing more slowly?


Patent expirations and a new pricing regime in the United States are weighing on two of its biggest drugs. Cosentyx, a treatment for psoriasis and other inflammatory diseases, brought in $6.67 billion in 2025, an increase of 9%. Chief executive Vas Narasimhan said on the analyst call that it should peak in 2027.


Under Medicare price negotiation, part of the Inflation Reduction Act, Cosentyx will see a price cut starting in 2028. The drug then loses exclusivity in 2029, when lower-priced biosimilar versions can begin to compete. The breast cancer drug Kisqali, which had sales of $4.78 billion last year, faces its own negotiated price cut in 2028.


Narasimhan said Kisqali should grow again after that and reach about $10 billion in sales around 2030. Last year the company described that goal as $10 billion plus. Asked by an analyst about the missing plus, he called its removal a policy decision rather than a lower forecast.


The company's announcement framed the year in stark terms. Narasimhan said in the release:


"In 2026 we expect to grow through the largest loss-of-exclusivity impact in our history."

The bet is on drugs most people have not heard of yet


Novartis is plugging the gap with higher sales targets for several newer drugs. Kesimpta, its multiple sclerosis drug, has a new peak sales target of $8 billion, up from $6 billion. It raised its targets for Scemblix for leukemia and Leqvio for cholesterol to $5 billion each.


Remibrutinib, sold under the brand name Rhapsido for chronic hives, already carries an $8 billion target across hives and multiple sclerosis. Novartis counts nine drugs on the market that could each reach peak yearly sales of $3 billion to $10 billion.


The pipeline is the other half of the pitch. Novartis expects more than 35 readouts through 2031 that could support approval filings for new medicines. Ten late-stage drugs carry multibillion-dollar peak sales guidance, including pelabresib for a bone marrow cancer and ianalumab for lupus.


Narasimhan said Novartis does not need to win them all. On the investor call, he told analysts that only two or three of the programs in the pipeline need to succeed. He described the company's task this way:


"The real question is, do you have the replacement power to come back out? And we believe we're showing you that we do."

AI is now part of the growth plan


Novartis argues that AI can improve both the speed and the success rate of its drug development. Its investor presentation sets an aspiration to raise the chance that a drug makes it from Phase I to registration from about 8% to about 12%. It also aims to cut development time from about 12 years to about 8.


Novartis says 95% of its small molecule projects are AI-enabled, with active compound rates up by as much as 70% in those projects. It also says it mapped 130,000 preclinical safety findings with 90% accuracy in weeks instead of years.


Novartis is not just using AI in the lab. It says clinical study reports are about 25% faster to write and review, with 90% of the content AI-assisted. Almost all of its US sales representatives use AI to decide the next action to take with customers.


For Silicon Valley, the presentation reads like a sales pitch for much of the AI software stack. Agentic clinical operations, generative chemistry and predictive safety models are all on its list of priority projects. They are also the areas that Bay Area AI startups are building to sell into pharma.


Gloved hands hold a 96 well compound plate in front of a monitor showing AI generated molecular structures and a ranked list of candidates

Half the future revenue could come from outside Novartis


Novartis wants to buy a large share of its future growth from smaller companies. Ronny Gal, its chief strategy and growth officer, said that over the long term Novartis expects about half its revenue to come from external assets. He said the company will focus mainly on deals of $2 billion or less in early-stage research.


The growth forecast does not assume any large acquisition. Narasimhan said it is based on medicines already in the Novartis portfolio, so any deals would add to that growth.


This is good news for founders who license out early science. Sparknify's July profile of Pharmasaga looked at how a Taiwanese biotech turned Academia Sinica research into PS-001, a diabetes drug now in a Phase I study. Small programs like that are the kind of early asset big drugmakers say they want to license or buy.


What will the patent cliff mean for patients, founders and investors?


The next five years will test whether a big drugmaker can replace its blockbusters faster than they fade. Novartis has set a modest public bar. If two or three late-stage programs succeed, its pitch is that growth can hold in the mid-single digits after 2031.


Bay Area biotech startups and their investors have reason to pay attention. A large company that wants half its revenue from outside sources should stay a steady buyer through licensing deals and acquisitions. Deals of $2 billion or less fit many venture-backed startups, and AI drug discovery companies gain a buyer that publishes its own productivity numbers.


There are risks for Novartis and for the companies hoping to do business with it. Novartis already absorbed late-stage failures this year on drugs it had acquired, a reminder that buying science is no guarantee of success. Its AI targets, including a 12% success rate, are goals and not results. Drug development takes so long that the payoff may not show until after 2031.


Pricing is the biggest political fault line in the plan. Supporters of Medicare negotiation say it will lower costs for older patients who need expensive drugs like Cosentyx and Kisqali. Drugmakers argue that lower prices on mature drugs reduce the money available for new research.


Patients may see a mixed picture, with lower prices on some older drugs from negotiation and generics. The new drugs Novartis is relying on will arrive at launch prices, and their value depends on clinical trial data that has not been seen yet.


Five things will show which way this goes.


  1. Medicare's negotiated prices for Cosentyx and Kisqali taking effect in 2028.

  2. Phase III results for pelabresib, ianalumab and abelacimab over the next two years.

  3. Novartis deals of $2 billion or less with early-stage biotechs, including Bay Area startups.

  4. Whether Kesimpta, Scemblix and Leqvio sales track toward their raised peak targets.

  5. Evidence that AI is shortening Novartis trials, starting with enrollment forecasts across all studies in 2027.


The patent cliff is coming for every big drugmaker, and Novartis has bet that new science, small deals and AI can carry it across.


Subscribe to Sparknify for tech news and the people behind it.


Questions & Answers


Q1: I run an early-stage biotech in the Bay Area. Does Novartis wanting half its revenue from outside assets mean more business for companies like mine?


Perhaps. Novartis chief strategy and growth officer Ronny Gal said the company will focus on deals of $2 billion or less in early-stage research, which covers many venture-backed biotechs. How buyers judge a deal matters as much as the science, a theme explored in conversations with investors on how they size up a deal.


Q2: How does early research from universities and institutes end up in the pipelines of big drugmakers like Novartis?


Often through a license, or through a startup that licenses the science and later partners with a drugmaker. Novartis says outside assets could account for half its long-term revenue. The licensing step was the topic of a Sunnyvale forum on moving research from lab to market, with a keynote from Stanford's Office of Technology Licensing.


Q3: What can a small biotech do to get on the radar of business development teams at Novartis and other large drugmakers?


A buyer wants clear clinical data and a good story around the science. Novartis said it prefers a number of smaller deals in early-stage research rather than one big acquisition. Founders who want their milestones covered can use a startup PR service built for that kind of outreach.

Comments


Upcoming Events

No events at the moment

More Articles

Subscribe to Latest Sparknify News and Event Notifications

Current Role
bottom of page